BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 1998/2/91 分で読めます

American Medical Systems Inc.; Premarket Approval of the UroLumeSUPTM/SUP Endourethral Prostatic for Prostatic Obstruction Secondary to Benign Prostatic Hypertrophy

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing its approval of the application by American Medical Systems Inc., Minnetonka, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the UroLume TM Endourethral Prostatic for Prostatic Obstruction Secondary to Benign Prostatic Hypertrophy (BPH). After reviewing the recommendation of the Gastroenterology-Urology Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of April 11, 1997, of the approval of the application.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

関連インサイト

ビジネスインサイト →